CCTA to Routinely Guide Invasive Management in Patients With CABG: Over-Testing or Essential?
- PMID: 39286900
- DOI: 10.1161/CIRCINTERVENTIONS.124.014605
CCTA to Routinely Guide Invasive Management in Patients With CABG: Over-Testing or Essential?
Keywords: Editorials; coronary artery bypass; ischemia; myocardial infarction; saphenous vein.
Conflict of interest statement
Dr Berry is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have interests in the management of angina. The companies include Abbott Vascular, AstraZeneca, Auxilius Pharma, Boehringer Ingelheim, CorFlow, Coroventis, HeartFlow, Siemens Healthcare, Therox, and Valo Health. The other authors report no conflicts.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
